Siow-Ming Lee

Professor of Medical Oncology, Consultant Oncologist, University College London (UCL) and UCL Hospitals (UCLH) .

Professor Lee trained in medicine at St. Mary’s Hospital Medical School, undertook postgraduate internal medicine training at St Bartholomew’s and King’s College Hospitals before completing his CRUK clinical oncology fellowship training at Guy’s and Christie Hospitals. He was awarded the American Association for Cancer Research Upjohn Award in 1993, McElwain Prize by the Association of Cancer Physicians in 1994, and a PhD degree from University of Manchester in 1994. He was appointed Consultant Medical Oncologist at UCLH in 1998, Fellow of The Royal College of Physicians in 2003 and Professor of Medical Oncology at UCL in 2010. He specializes in the treatment of lung and HIV cancers.

He is currently recognized as one of the leading international researchers in lung cancer and has conducted several randomised lung cancer trials including the first randomised phase III study in advanced NSCLC specifically designed to evaluate prospective testing of ERCC1 as a predictive biomarker for platinum chemotherapy. His lung research work has been recognised at major international cancer meetings with several invited Presidential, Plenary and Oral lectures at World Lung Cancer Conference, ASCO and ESMO. He has published extensively, with many as first or senior author in high ranking peer-reviewed journals including Lancet Oncology, JCO, JNCI, Cancer Research, Lancet and Science including several seminal publications: i) first human trial to show tumour DNA repair protein plays an important role in causing cytotoxic drug resistance which subsequently leads to the concept of designing small molecule inhibitors, ii) the 5-day activity of oral temozolomide is due to the cumulative depletion of the DNA repair protein, MGMT and this treatment schedule continues to remain the standard treatment for high grade glioma, iii) his dataset on advanced Hodgkin’s disease contributed to the International Hasenclever Index for Hodgkins disease after he conducted the first study to show it is not possible to identify a poor risk group to warrant auto transplantation after standard chemotherapy, iv) establish the routine use of G-CSF after auto transplant which leads to faster haematological recovery and shorter hospital stays.
Professor Lee is currently a clinical co-lead at the Cancer Research UK (CRUK) Lung Cancer Centre of Excellence, chairs the London Lung Cancer Group, which has a longstanding (>30 years) international research reputation, previous committee member of CTACC and past chair of the NCRI Lung Cancer Advanced Disease Subgroup and Brain New-agents Clinical Subgroup. He also sits on several national and international executive cancer committees.